Still sifting data from a Phase III study of its obesity drug Axokine, Regeneron Pharmaceuticals Inc. disclosed preliminary results from a Phase II trial in which the treatment yielded statistically significant weight loss in obese people with diabetes. (BioWorld Today) Read More
